XNASNARI
Market cap4.64bUSD
Jan 08, Last price
79.30USD
1D
-0.19%
1Q
95.18%
IPO
86.54%
Name
Inari Medical Inc
Chart & Performance
Profile
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
Income | ||||||
Revenues | 493,632 28.73% | 383,471 38.45% | ||||
Cost of revenue | 497,264 | 411,570 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (3,632) | (28,099) | ||||
NOPBT Margin | ||||||
Operating Taxes | 5,882 | 3,082 | ||||
Tax Rate | ||||||
NOPAT | (9,514) | (31,181) | ||||
Net income | (1,636) -94.41% | (29,267) -397.43% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 9,921 | 177,138 | ||||
BB yield | -0.27% | -5.27% | ||||
Debt | ||||||
Debt current | 3,384 | 1,311 | ||||
Long-term debt | 62,402 | 63,263 | ||||
Deferred revenue | ||||||
Other long-term liabilities | 66,400 | |||||
Net debt | (51,166) | (270,127) | ||||
Cash flow | ||||||
Cash from operating activities | 35,927 | (13,972) | ||||
CAPEX | (4,710) | (9,951) | ||||
Cash from investing activities | (58,018) | (195,216) | ||||
Cash from financing activities | 1,171 | 177,138 | ||||
FCF | 1,665 | (56,413) | ||||
Balance | ||||||
Cash | 115,452 | 326,401 | ||||
Long term investments | 1,500 | 8,300 | ||||
Excess cash | 92,270 | 315,527 | ||||
Stockholders' equity | (39,543) | (45,947) | ||||
Invested Capital | 590,920 | 495,236 | ||||
ROIC | ||||||
ROCE | ||||||
EV | ||||||
Common stock shares outstanding | 56,771 | 52,838 | ||||
Price | 64.92 2.14% | 63.56 -30.36% | ||||
Market cap | 3,685,551 9.74% | 3,358,363 -33.81% | ||||
EV | 3,634,385 | 3,088,236 | ||||
EBITDA | 7,103 | (20,980) | ||||
EV/EBITDA | 511.67 | |||||
Interest | 196 | 294 | ||||
Interest/NOPBT |